EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of semaglutide 7.2 mg in obesity: STEP UP trial

Iskandar Idris, Sean Wharton, Paula Freitas, Joran Hjelmesaeth, Maria Kabisch, Kristian Kandler, Ildiko Lingvay, Los Angeles Quiroga Pelaez Maria De, Julio Rosenstock, W. Timothy Garvey

Obesity Abstracts · 28.11.2025

DOI: 10.1530/obabs.05.p3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity Abstracts, online erschienen am 28.11.2025. Verfasst von Iskandar Idris und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Idris, I., Wharton, S., Freitas, P., Hjelmesaeth, J., Kabisch, M., Kandler, K., Lingvay, I., De, L. A. Q. P. M., Rosenstock, J., & Garvey, W. T. (2025). Efficacy and safety of semaglutide 7.2 mg in obesity: STEP UP trial. Obesity Abstracts. https://doi.org/10.1530/obabs.05.p3

Vancouver

Idris I, Wharton S, Freitas P, Hjelmesaeth J, Kabisch M, Kandler K, et al. Efficacy and safety of semaglutide 7.2 mg in obesity: STEP UP trial. Obesity Abstracts. 2025. doi:10.1530/obabs.05.p3

BibTeX
@article{Idris2025,
  author = {Idris, Iskandar and Wharton, Sean and Freitas, Paula and Hjelmesaeth, Joran and Kabisch, Maria and Kandler, Kristian and Lingvay, Ildiko and De, Los Angeles Quiroga Pelaez Maria and Rosenstock, Julio and Garvey, W. Timothy},
  title = {Efficacy and safety of semaglutide 7.2 mg in obesity: STEP UP trial},
  journal = {Obesity Abstracts},
  year = {2025},
  doi = {10.1530/obabs.05.p3}
}
Kostenlos starten →